×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at ASCO 2015

Results from studies involving Amgen's oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29-June 2.

Abstracts are available on the ASCO website at http://am.asco.org/abstracts and updated data will be presented at the meeting.

If you are at ASCO, stop by Amgen's booth #18041 to learn more about Amgen Oncology.

Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during ASCO.


June 1, 2015 Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors
May 13, 2015 Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio